Myeloproliferative Neoplasms | Specialty

The myeloproliferative neoplasms condition center is a comprehensive resource for clinical news on myeloproliferative neoplasms. Read more at OncLive.

IHC Testing Leads to Early Detection of TP43-Mutant AML and MDS: With Jonathan M. Gerber, MD; and Shyam A. Patel, MD, PhD

July 16th 2025

Drs Gerber and Patel discuss a study they conducted investigating the use of IHC as a biomarker for early TP53 mutation identification in MDS and AML.

Data for Elotuzumab Support Further Investigation in JAK Inhibitor–Based Combinations in Myelofibrosis

July 15th 2025

Safety and efficacy data for elotuzumab support its further investigation in the treatment of myelofibrosis.

Dr Kremyanskaya on the Mechanism of Action of Divesiran in Polycythemia Vera

July 11th 2025

Marina Kremyanskaya, MD, PhD, details the mechanism of action of divesiran for the treatment of patients with polycythemia vera.

How Data Are Defining the Role of Luspatercept in ESA-Naive, Lower-Risk MDS

July 10th 2025

Guillermo Garcia-Manero, MD, highlights clinical trial findings and real-world data for luspatercept in ESA-naive, lower-risk MDS.

Five Under 5: Top Oncology Videos for the Week of 6/29

July 6th 2025

The top 5 OncLive videos of the week cover insights in myelofibrosis, AL amyloidosis, pancreatic cancer, and PIK3CA-mutated breast cancer.

Dr Daver on Initial Efficacy and Safety Data With Bexmarilimab Plus Azacitidine in Higher-Risk MDS

July 2nd 2025

Naval G. Daver, MD, discusses early efficacy and safety data for bexmarilimab plus azacitidine in patients with higher-risk myelodysplastic syndrome.

Dr Mascarenhas on the Safety of Imetelstat Plus Ruxolitinib in Higher-Risk Myelofibrosis

June 30th 2025

John O. Mascarenhas, MD, discusses the safety profile of imetelstat plus ruxolitinib in patients with higher-risk myelofibrosis.

Five Under 5: Top Oncology Videos for the Week of 6/22

June 29th 2025

The top 5 OncLive videos of the week cover insights in myelofibrosis, lung cancer, ovarian cancer, breast cancer, and melanoma.

Dr Palandri on Outcomes With Momelotinib in Myelofibrosis Per Dual SVR35 and Transfusion Independence

June 27th 2025

Francesca Palandri, MD, shares SVR35 rates with momelotinib vs ruxolitinib across patient subgroups in the anemic subpopulation of SIMPLIFY-1.

OS Data From COMMANDS for Luspatercept in ESA-Naive, Lower-Risk MDS

June 26th 2025

Guillermo Garcia-Manero, MD, discusses OS data from the COMMANDS trial for luspatercept in ESA-naive, lower-risk MDS.

Dr Kuykendall on the Rationale for Targeting the Hepcidin Pathway With Rusfertide in Polycythemia Vera

June 24th 2025

Andrew Kuykendall, MD, discusses the rationale for using rusfertide to target the hepcidin pathway in patients with polycythemia vera.

Dr Mascarenhas on the Efficacy of Imetelstat Plus Ruxolitinib in Higher-Risk Myelofibrosis

June 23rd 2025

John O. Mascarenhas, MD, discussed findings from the IMproveMF trial investigating imetelstat plus ruxolitinib in patients with higher-risk myelofibrosis.

Gecacitinib Elicits Hematologic Responses, Spleen and Symptom Reduction Across Anemic Subgroups in Myelofibrosis

June 23rd 2025

Gecacitinib, a dual JAK/ACVR1 inhibitor, showed spleen volume, symptom and anemia improvements in patients with myelofibrosis.

Dr Amanam on the Real-World Efficacy of First-Line Luspatercept vs Erythropoiesis-Stimulating Agents in Lower-Risk MDS

June 23rd 2025

Idoroenyi Amanam, MD, discusses the efficacy of first-line luspatercept vs erythropoiesis-stimulating agents in real-world patients with lower-risk MDS.

The OncFive: Top Oncology Articles for the Week of 6/15

June 21st 2025

Tafasitamab combination gets approval in follicular lymphoma, FDA declines to expand label for talazoparib plus enzalutamide in mCRPC, and more.

Recent Shifts in the Management of Lower-Risk MDS

June 19th 2025

Guillermo Garcia-Manero, MD, highlights recent shifts in the lower-risk myelodysplastic syndrome treatment paradigm.

Dr Komrokji on the Effect of Prior Treatment on Imetelstat Activity in Transfusion-Dependent LR-MDS

June 18th 2025

Rami Komrokji, MD, shares results from a pooled analysis of outcomes with imetelstat based on prior therapy in transfusion-dependent lower-risk MDS.

FDA Grants Orphan Drug Designation to SENTI-202 for R/R AML and Hematologic Malignancies

June 18th 2025

SENTI-202 receives FDA orphan drug designation for treating relapsed/refractory hematologic malignancies, including AML.

Hematologists Highlight Notable Insights From the 2025 EHA Congress

June 18th 2025

Hematologic oncology experts share the studies they were most excited to see presented at the 2025 EHA Congress.

Post Hoc Analysis Shows Imetelstat Drives Benefit in RS-Negative, Lower-Risk MDS

June 17th 2025

Imetelstat demonstrated clinical benefits in patients with ring sideroblast–negative lower-risk MDS, according to a post hoc analysis.